Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities
- PMID: 1361435
- DOI: 10.1159/000474760
Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities
Abstract
A double-blind, placebo-controlled study in 20 patients with 'prostatitis syndromes' and confirmed urodynamic abnormalities using the alpha 1-receptor-blocking compound alfuzosin is reported. Flow rate recordings are probably the most reliable and useful objective variables in this type of investigation. There is a significant beneficial effect in the group using an active compound concerning maximal flow (p = 0.01), flow time (p = 0.03) and time to maximal flow (p = 0.01). However, compared with the group using a placebo, only the change in the maximal flow rate appeared to be significantly different. Subjective effects were more pronounced in the alfuzosin group, but the spurious nature of the subjective observations is stressed. Based on objective parameters, alfuzosin seems to be effective compared to placebo in the treatment of these patients with micturition complaints of an irritative nature and urodynamic abnormalities, while only minor side effects were noticed.
Similar articles
-
Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study.Urology. 2003 Sep;62(3):425-9. doi: 10.1016/s0090-4295(03)00466-7. Urology. 2003. PMID: 12946740 Clinical Trial.
-
Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.Eur Urol. 1997;32(1):47-53. Eur Urol. 1997. PMID: 9266231 Clinical Trial.
-
Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome.N Engl J Med. 2008 Dec 18;359(25):2663-73. doi: 10.1056/NEJMoa0803240. N Engl J Med. 2008. PMID: 19092152 Free PMC article. Clinical Trial.
-
Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.Urology. 2005 Oct;66(4):780-8. doi: 10.1016/j.urology.2005.05.001. Urology. 2005. PMID: 16230138 Review.
-
Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. doi: 10.1016/s0090-4295(01)01322-x. Urology. 2001. PMID: 11750253 Review.
Cited by
-
A MOF-Templated Double-Shelled Co3O4/NiCo2O4 Nanocomposite for Electrochemical Detection of Alfuzosin.Nanomaterials (Basel). 2024 Apr 25;14(9):757. doi: 10.3390/nano14090757. Nanomaterials (Basel). 2024. PMID: 38727351 Free PMC article.
-
Role of alpha blocker therapy in chronic prostatitis/chronic pelvic pain syndrome: limited options with promising results.Indian J Surg. 2008 Oct;70(5):215-8. doi: 10.1007/s12262-008-0062-4. Epub 2008 Nov 26. Indian J Surg. 2008. PMID: 23133065 Free PMC article.
-
Tamsulosin Monotherapy versus Combination Therapy with Antibiotics or Anti-Inflammatory Agents in the Treatment of Chronic Pelvic Pain Syndrome.Int Neurourol J. 2011 Jun;15(2):92-6. doi: 10.5213/inj.2011.15.2.92. Epub 2011 Jun 30. Int Neurourol J. 2011. PMID: 21811699 Free PMC article.
-
Chronic prostatitis.BMJ Clin Evid. 2011 Jul 4;2011:1802. BMJ Clin Evid. 2011. PMID: 21736764 Free PMC article. Review.
-
Chronic prostatitis.BMJ Clin Evid. 2008 May 22;2008:1802. BMJ Clin Evid. 2008. PMID: 19450305 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical